Identification of C2orf18 as a Key Molecule in Pancreatic Carcinogenesis

Strategic Insights -

Researchers at the University of Tokyo have made a groundbreaking discovery in the field of pancreatic cancer research. They identified a novel gene, C2orf18, also known as ANT2-binding protein (ANT2BP), as a crucial molecule involved in the development of pancreatic ductal adenocarcinoma (PDAC). This type of cancer has one of the worst mortality rates among common malignancies, with most patients diagnosed at an advanced stage with no effective treatment available. The study, published in Cancer Science, highlights the urgent need for novel molecular targets and therapies for PDAC.

Key Takeaways:

  • The researchers used genome-wide gene expression profiles of microdissected PDAC cells to identify novel gene C2orf18 as a molecular target for PDAC treatment.
  • Transcriptional and immunohistochemical analysis validated the overexpression of C2orf18 in PDAC cells and limited expression in normal adult organs.
  • Knockdown of C2orf18 by small-interfering RNA in PDAC cell lines resulted in induction of apoptosis and suppression of cancer cell growth, suggesting its essential role in maintaining viability of PDAC cells.
  • C2orf18 was localized in the mitochondria and interacted with adenine nucleotide translocase 2 (ANT2), involved in maintenance of the mitochondrial membrane potential and energy homeostasis.
  • The study suggests that C2orf18 (ANT2BP) might serve as a candidate molecular target for pancreatic cancer therapy.
  • The research was conducted by K. Kashiwaya and colleagues at the University of Tokyo, Institute of Medical Science.
  • The study has significant implications for the development of molecular therapies for PDAC.

Statistics:

  • Pancreatic ductal adenocarcinoma (PDAC) has one of the worst mortality rates among common malignancies, with few effective treatment options available (Source: Cancer Science, 2009;100(3):457-64).
  • The study identified a novel gene, C2orf18 (ANT2BP), as a molecular target for PDAC treatment (Source: Cancer Science, 2009;100(3):457-64).
  • Knockdown of C2orf18 resulted in induction of apoptosis in PDAC cell lines, suggesting its essential role in maintaining viability of PDAC cells (Source: Cancer Science, 2009;100(3):457-64).

Sources:

  • Cancer Science (2009;100(3):457-64)
  • Gene Therapy (no specific date mentioned)
  • NewsRx.com via Gene Therapy Weekly (no specific date mentioned)